



261 Mountain View Dr
 Colchester, VT 05446
 License #: TLAB0030
 802-767-7256
 info@onwardanalytics.biz

Certificate of Analysis

Client Name: Vermont Kind
License Number: SCLT0186 MANU0027

Sample ID: 20260203-29023
Sample Name: Queen's Sangria Virgin Extract
Sample Lot: MANU0027-C0103
Sample Matrix: Solvent Extraction Concentrates
Date Received: 2/3/2026
Date Reported: 2/10/2026
Date Tested: 2/4/2026



Total Terpenes (%) : 7.5859

Dominant Terpenes (%)	
Myrcene	2.1723
beta-caryophyllene	1.912
Limonene	0.6898
alpha-Humulene	0.6691
alpha-Pinene	0.4816

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #95456

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.4796	4.796	0.000003	0.001
alpha-Humulene	0.6691	6.691	0.000002	0.001
alpha-Pinene	0.4816	4.816	0.000001	0.001
alpha-Terpinene	0.0373	0.373	0.000001	0.001
alpha-Terpinolene	0.0355	0.355	0.000004	0.001
beta-caryophyllene	1.912	19.12	0.000004	0.001
beta-Pinene	0.259	2.59	0.000002	0.001
Camphene	0.0344	0.344	0.000001	0.001
Caryophyllene Oxide	0.1173	1.173	0.000011	0.001
Eucalyptol	0.0328	0.328	0.000002	0.001
gamma-Terpinene	ND	ND	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	0.2112	2.112	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.6898	6.898	0.000002	0.001
Linalool	0.1898	1.898	0.000003	0.001
Nerolidol	0.0603	0.603	0.000007	0.001
Myrcene	2.1723	21.723	0.000003	0.001
Ocimene	0.2039	2.039	0.000002	0.001
Total Terpenes	7.5859	75.859		



Callie Chapman
 Callie Chapman
 Lab Director
 2/10/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

